We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

40 hedge funds and large institutions have $14.2M invested in Aevi Genomic Medicine Inc in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

9% less funds holding

Funds holding: 44 → 40 (-4)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

48% less capital invested

Capital invested by funds: $27.2M → $14.2M (-$13M)

50% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 8

Holders
40
Holders Change
-4
Holders Change %
-9.09%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
8
Closed
8
Calls
$33K
Puts
–
Net Calls
+$33K
Net Calls Change
+$6K

Top Buyers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
+$318K
2
BlackRock
BlackRock
New York
+$60K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$50.5K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$41.6K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$29.5K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.32M
2
JP Morgan Chase
JP Morgan Chase
New York
-$203K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$63K
4
TD Asset Management
TD Asset Management
Ontario, Canada
-$57.8K
5
Renaissance Technologies
Renaissance Technologies
New York
-$43.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$6K +$2.48K +1,631 +46%
LA
27
Legacy Advisors
Pennsylvania
$3K – – –
MAM
28
Meeder Asset Management
Ohio
$2.6K -$354 -233 -9%
KCPG
29
Kavar Capital Partners Group
Kansas
$2K – – –
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$2K – – –
Royal Bank of Canada
31
Royal Bank of Canada
Ontario, Canada
$2K – – –
Bank of America
32
Bank of America
North Carolina
$1K – – –
IA
33
IFP Advisors
Florida
$1K – – –
KTC
34
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
TWA
35
TCI Wealth Advisors
Arizona
$1K – – –
UBS Group
36
UBS Group
Switzerland
$1K – – –
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$2 – – –
JP Morgan Chase
38
JP Morgan Chase
New York
– -$203K -101,118 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$63K -31,338 Closed
Citadel Advisors
40
Citadel Advisors
Florida
– -$24K -12,021 Closed
Northwestern Mutual Wealth Management
41
Northwestern Mutual Wealth Management
Wisconsin
– -$20K -10,000 Closed
WAP
42
Wealthcare Advisory Partners
Pennsylvania
– -$10K -5,000 Closed
IWM
43
IHT Wealth Management
Illinois
– -$2K -1,000 Closed
AG
44
Advisor Group
Arizona
– -$1K -525 Closed
Barclays
45
Barclays
United Kingdom
– -$2 -1 -1%
Simplex Trading
46
Simplex Trading
Illinois
– +$32 +21 New
1
2

GNMX Hedge Fund Activity: Q2 2018 in Review

40 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2018, worth a combined $14.2M — down 48% from $27.2M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of GNMX and 4 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Wedbush Securities, opening a new position worth an estimated $318K. The largest seller was T. Rowe Price Associates, cutting an estimated $1.32M.

  • 40 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2018, down from 44 in Q1 2018.
  • Funds reported $14.2M of Aevi Genomic Medicine Inc stock for Q2 2018, down 48% quarter-over-quarter.
  • 4 funds opened new Aevi Genomic Medicine Inc positions in Q2 2018 and 8 closed out, a net change of -4 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q2 2018 was Wedbush Securities, an estimated $318K added.
  • The largest Aevi Genomic Medicine Inc seller in Q2 2018 was T. Rowe Price Associates, an estimated $1.32M sold.

Based on aggregated 13F filings for Q2 2018.